Head and Neck Carcinoma Clinical Trials & Research at St. Joseph Health
Medical Group
Head and neck cancers start in the tissues and organs of the head and neck
and include cancers of the larynx (voice box), throat, lips, mouth, nose,
and salivary glands. Most head and neck cancers are squamous cell carcinomas
and begin in the moist tissues that line the mouth, nose and throat. Tobacco
use, heavy alcohol use, and infection with the human papillomavirus (HPV)
increase your risk of head and neck cancer.
St. Joseph Health Medical Group is currently enrolling patients for the
following head and neck carcinoma clinical trial:
A Randomized Phase III study of pembrolizumab given concomitantly with
chemoradiation and as maintenance therapy versus chemoradiation alone
in subjects with locally advanced head and neck squamous cell carcinoma
(KEYNOTE-412)
Phase III
The purpose of this study is to determine the efficacy and safety of pembrolizumab
given concomitantly with chemoradiation (CRT) and as maintenance therapy
versus placebo plus CRT in participants with locally advanced head and
neck squamous cell carcinoma. The primary hypothesis is that pembrolizumab
in combination with CRT is superior to placebo in combination with CRT
with respect to event-free survival.
Treatment agent: Pembrolizumab
PI:
Thomas Stanton, MD
Study Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links:
clinicaltrials.gov NCT No: NCT03428217